AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19912243 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI 30 mg + KI
Number of subjects: 134
Study 19912243 — intervention group
Group type: COMPARATOR
Intervention: MMI 15 mg
Number of subjects: 134
Study 19912243 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI 15 mg + KI
Number of subjects: 134
Study 19912243 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 1, 2, 3, and 4
Number of subjects: 134
Study 17879223 — intervention group
Group type: EXPERIMENTAL
Intervention: email bulimia therapy (eBT)
Number of subjects: 97
Study 17879223 — intervention group
Group type: EXPERIMENTAL
Intervention: unsupported Self directed writing (SDW)
Number of subjects: 97
Study 17879223 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 97
Study 17879223 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck depression inventory (BDI)
Number of subjects: 97
Study 17879223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia investigatory test (BITE)
Number of subjects: 97
Study 17012875 — intervention group
Group type: EXPERIMENTAL
Intervention: rDEN1Delta30 vaccine (10^3 pfu)
Number of subjects: 28
Study 17012875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14616413 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg twice daily)
Number of subjects: 0
Study 14616413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10739846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannan-binding lectin concentration during pregnancy
Number of subjects: 14
Study 8741449 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion cardioplegia with recirculation type circuit
Number of subjects: 0
Study 8741449 — intervention group
Group type: COMPARATOR
Intervention: Single pass type cardioplegia circuit
Number of subjects: 0
Study 1424618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg single dose)
Number of subjects: 16
Study 1424618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3881303 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% complex carbohydrates and 20% simple carbohydrates (80/20)
Number of subjects: 12
Study 3881303 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% complex carbohydrates and 50% simple carbohydrates (50/50)
Number of subjects: 12
Study 3881303 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% complex carbohydrates and 80% simple carbohydrates (20/80)
Number of subjects: 12
Study 3881303 — intervention group
Group type: COMPARATOR
Intervention: All diets
Number of subjects: 12
Study 31912285 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiduroscopy with mechanical lysis of adhesions
Number of subjects: 79
Study 31912285 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiduroscopy with mechanical lysis of adhesions and medication (methylprednisolone and hyaluronidase)
Number of subjects: 79
Study 31912285 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiduroscopy
Number of subjects: 79
Study 31531963 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Number of subjects: 52
Study 28883722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol (AB/FF) 400/12 μg twice daily
Number of subjects: 267
Study 28883722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 26003121 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light Poster (TFP) intervention
Number of subjects: 58
Study 23881929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (VEGF-targeted agent)
Number of subjects: 225
Study 21241468 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ranibizumab (Lucentis®) eye drops (2 mg/ml) four times daily for 1 month
Number of subjects: 5
Study 21241468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BSS 4x/d for 1 month)
Number of subjects: 5
Study 19592748 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 45
Study 19592748 — intervention group
Group type: COMPARATOR
Intervention: non-VR group
Number of subjects: 45
Study 19592748 — intervention group
Group type: COMPARATOR
Intervention: waiting list group
Number of subjects: 45
Study 17163260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 24 mg on day 1 followed by 8 mg twice daily for 5 days
Number of subjects: 220
Study 17163260 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium 150 mg on day 1 followed by 50 mg twice daily for 5 days
Number of subjects: 220
Study 17163260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 220
Study 17163260 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac potassium
Number of subjects: 220
Study 12574810 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated-dose strategy (based on regression formula)
Number of subjects: 90
Study 12574810 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose strategy (fixed at 5 mg)
Number of subjects: 90
Study 12574810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 90
Study 10845831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 352
Study 10845831 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 352
Study 9109105 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF-14) 50 micrograms administered every hour between 2200 and 0100 hours
Number of subjects: 20
Study 9109105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 1546915 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of bacteremia (elevated temperature, low systolic blood pressure, low platelet count)
Number of subjects: 465
Study 1546915 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of gram-negative bacteremia (elevated temperature, low systolic blood pressure, low platelet count)
Number of subjects: 465
Study 3935298 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental doses of nalbuphine administered approximately four hours after cardiopulmonary bypass
Number of subjects: 20
Study 3935298 — intervention group
Group type: COMPARATOR
Intervention: Normal saline administered approximately four hours after cardiopulmonary bypass
Number of subjects: 20
Study 31359800 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiopaque cement
Number of subjects: 33
Study 31359800 — intervention group
Group type: COMPARATOR
Intervention: Radiolucent cement
Number of subjects: 33
Study 29735344 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS-40 μs
Number of subjects: 9
Study 29735344 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS-60 μs
Number of subjects: 9
Study 29735344 — intervention group
Group type: COMPARATOR
Intervention: DBS-OFF
Number of subjects: 9
Study 29441995 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus oxaliplatin (SOX) as perioperative chemotherapy (group A, 50 patients)
Number of subjects: 102
Study 29441995 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy (group B, 52 patients)
Number of subjects: 102
Study 25997014 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco cessation pharmacotherapies (specifics not provided)
Number of subjects: 1301
Study 23164226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota 3 times daily for 12 weeks
Number of subjects: 30
Study 23164226 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard medical therapy
Number of subjects: 30
Study 21347648 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 694
Study 21347648 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 694
Study 18626520 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of TTF-1
Number of subjects: 43
Study 18626520 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of CK7
Number of subjects: 43
Study 18626520 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of CK20
Number of subjects: 43
Study 18626520 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of TTF-1, CK7, and CK20 in mesotheliomas
Number of subjects: 43
Study 18626520 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining of TTF-1 in metastatic tumors
Number of subjects: 43
Study 16531939 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner treatment (PDPT)
Number of subjects: 463
Study 16531939 — intervention group
Group type: COMPARATOR
Intervention: Booklet-enhanced partner referral (BEPR)
Number of subjects: 463
Study 16531939 — intervention group
Group type: COMPARATOR
Intervention: Standard partner referral (PR)
Number of subjects: 463
Study 16531939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 463
Study 12744878 — intervention group
Group type: EXPERIMENTAL
Intervention: PFP-3 vaccine
Number of subjects: 294
Study 12744878 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant-control
Number of subjects: 294
Study 10586395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg once daily for 9 days
Number of subjects: 12
Study 10586395 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 9 days
Number of subjects: 12
Study 8738947 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection
Number of subjects: 263
Study 8738947 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate antibiotic therapy
Number of subjects: 263
Study 1662033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan 10 mg
Number of subjects: 12
Study 1662033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan 20 mg
Number of subjects: 12
Study 1662033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan 40 mg
Number of subjects: 12
Study 1662033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinorphan (all doses)
Number of subjects: 12
Study 7037047 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% epinephrine (EPI)
Number of subjects: 20
Study 7037047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dipivalyl epinephrine (DPE)
Number of subjects: 20
Study 7037047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31617335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg body weight) administered at 11 a.m. or 6 p.m. for 24 weeks
Number of subjects: 0
Study 31617335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) administered at 11 a.m. or 6 p.m. for 24 weeks
Number of subjects: 0
Study 29657029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic administration of FGF21
Number of subjects: 0
Study 29657029 — intervention group
Group type: EXPERIMENTAL
Intervention: Mice with normal FGF21 levels
Number of subjects: 0
Study 29657029 — intervention group
Group type: COMPARATOR
Intervention: Mice lacking FGF21
Number of subjects: 0
Study 29657029 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF21
Number of subjects: 0
Study 26891181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 138
Study 26891181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate in rs2832407*CC genotype
Number of subjects: 138
Study 26891181 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate in rs2832407*A-allele carriers
Number of subjects: 138
Study 24262513 — intervention group
Group type: EXPERIMENTAL
Intervention: Corinthian Raisins (CR) consumption (36 g/d, replacing snacks with similar energy density twice daily)
Number of subjects: 48
Study 24262513 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 24262513 — intervention group
Group type: EXPERIMENTAL
Intervention: Corinthian Raisins (CR) consumption (36 g/d)
Number of subjects: 48
Study 22101624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (3 mg/h for 2-3 h)
Number of subjects: 24
Study 22101624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21053624 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus cupping
Number of subjects: 92
Study 21053624 — intervention group
Group type: COMPARATOR
Intervention: Conventional differentiation of symptoms and signs
Number of subjects: 92
Study 17612054 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 16640173 — intervention group
Group type: EXPERIMENTAL
Intervention: Latest antihypertensive drugs
Number of subjects: 37000000
Study 16640173 — intervention group
Group type: COMPARATOR
Intervention: Older blood pressure strategies
Number of subjects: 37000000
Study 11937309 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised form-based reports
Number of subjects: 2042
Study 11937309 — intervention group
Group type: COMPARATOR
Intervention: Conventional free text reporting
Number of subjects: 2042
Study 10402687 — intervention group
Group type: EXPERIMENTAL
Intervention: High DSM‐III‐R avoidant personality pathology
Number of subjects: 57
Study 10402687 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant beliefs
Number of subjects: 57
Study 10402687 — intervention group
Group type: COMPARATOR
Intervention: Low DSM‐III‐R avoidant personality pathology
Number of subjects: 57
Study 10402687 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem
Number of subjects: 57
Study 10402687 — intervention group
Group type: COMPARATOR
Intervention: Social phobia and general personality pathology
Number of subjects: 57
Study 7743798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dosing regimen compatible with home use: two drops of 0.3% ciprofloxacin every 4 h over a 24‐h period (Group 1)
Number of subjects: 31
Study 7743798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dosing regimen applied by a trained professional: two drops of Ciloxan every 15 min over a 4‐h period (Group 2)
Number of subjects: 31
Study 7743798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin dosing regimen applied by a trained professional with corneas abraded (Group 3)
Number of subjects: 31
Study 1903409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitroglycerin (0.6 mg)
Number of subjects: 20
Study 1903409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6168124 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg p.o/day for 5 days
Number of subjects: 68
Study 6168124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 6168124 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 68
Study 31498919 — intervention group
Group type: EXPERIMENTAL
Intervention: RASB continuation
Number of subjects: 316
Study 31498919 — intervention group
Group type: COMPARATOR
Intervention: RASB discontinuation
Number of subjects: 316
Study 31498919 — intervention group
Group type: COMPARATOR
Intervention: Nonuse of RASB
Number of subjects: 316
Study 31498919 — intervention group
Group type: EXPERIMENTAL
Intervention: RASB initiation
Number of subjects: 316
Study 28659162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus herbal medicine and health education
Number of subjects: 80
Study 28659162 — intervention group
Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 80
Study 26497218 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychoeducational group intervention for relatives (4 sessions lasting 90 to 120 min each)
Number of subjects: 180
Study 26497218 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study 23427970 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handed curriculum (30-minute introductory video and 2-hour instructor-led training)
Number of subjects: 19
Study 23427970 — intervention group
Group type: COMPARATOR
Intervention: Right-handed curriculum (30-minute introductory video and 2-hour instructor-led training)
Number of subjects: 19
Study 21273912 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian rhythm of cortisol (C) and testosterone (T)
Number of subjects: 20
Study 21273912 — intervention group
Group type: EXPERIMENTAL
Intervention: 0800 and 2000 hours testing sessions
Number of subjects: 20
Study 21273912 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary testosterone (T) and cortisol (C) levels
Number of subjects: 20
Study 21273912 — intervention group
Group type: EXPERIMENTAL
Intervention: Taural
Number of subjects: 20
Study 21273912 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and power training or testing
Number of subjects: 20
Study 21273912 — intervention group
Group type: EXPERIMENTAL
Intervention: Session RPE
Number of subjects: 20
Study 19324953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-shift decrease in PEF of 5 L.min(‐1)
Number of subjects: 0
Study 19324953 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial PEF records analysis using linear discriminant analysis
Number of subjects: 0
Study 19324953 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean work/rest day PEF comparison
Number of subjects: 0
Study 19324953 — intervention group
Group type: COMPARATOR
Intervention: Cross-shift changes in PEF
Number of subjects: 0
Study 17785973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion (SI) of piperacillin/sulbactam (4/1 g every 8 h)
Number of subjects: 7
Study 17785973 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) of piperacillin/sulbactam (8/2 g per 24 h after loading dose)
Number of subjects: 7
Study 12589521 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg orally)
Number of subjects: 14
Study 12589521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (20 mg orally)
Number of subjects: 14
Study 12589521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of buspirone and pindolol
Number of subjects: 14
Study 12589521 — intervention group
Group type: COMPARATOR
Intervention: Buspirone (30 mg orally) with Pindolol (20 mg orally)
Number of subjects: 14
Study 10783215 — intervention group
Group type: EXPERIMENTAL
Intervention: SAK42D 15 mg
Number of subjects: 82
Study 10783215 — intervention group
Group type: EXPERIMENTAL
Intervention: SAK42D 30 mg
Number of subjects: 82
Study 10783215 — intervention group
Group type: EXPERIMENTAL
Intervention: SAK42D 45 mg
Number of subjects: 82
Study 10783215 — intervention group
Group type: EXPERIMENTAL
Intervention: SAK42D
Number of subjects: 82
Study 9816275 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA 125 mg/m2
Number of subjects: 88
Study 9816275 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA 250 mg/m2
Number of subjects: 88
Study 9816275 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA 500 mg/m2
Number of subjects: 88
Study 9816275 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA 1000 mg/m2
Number of subjects: 88
Study 9816275 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 400 mg/m2
Number of subjects: 88
Study 9816275 — intervention group
Group type: EXPERIMENTAL
Intervention: DP 50 mg/m2
Number of subjects: 88
Study 9816275 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU dose escalation
Number of subjects: 88
Study 1576631 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem-cilastatin (I-C)
Number of subjects: 94
Study 1576631 — intervention group
Group type: COMPARATOR
Intervention: clindamycin+gentamicin (C+G)
Number of subjects: 94
Study 3930257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 6
Study 3930257 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 6
Study 2829267 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93,426 (0.01 mg/kg)
Number of subjects: 0
Study 2829267 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 93,426 (0.04 mg/kg)
Number of subjects: 0
Study 2829267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30475969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g protein · kg‐1 · d‐1
Number of subjects: 120
Study 30475969 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g protein · kg‐1 · d‐1
Number of subjects: 120
Study 28222641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid genotyping-guided treatment (GG)
Number of subjects: 132
Study 28222641 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SG)
Number of subjects: 132
Study 26135562 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor (150 mg)
Number of subjects: 152
Study 26135562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 23908481 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 773
Study 20394809 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-DMH (dimenhydrinate)
Number of subjects: 9
Study 20394809 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-Scop (scopolamine)
Number of subjects: 9
Study 20394809 — intervention group
Group type: COMPARATOR
Intervention: MS-CN (control, no medication, MS provocation)
Number of subjects: 9
Study 20394809 — intervention group
Group type: COMPARATOR
Intervention: MS-P (placebo)
Number of subjects: 9
Study 20394809 — intervention group
Group type: COMPARATOR
Intervention: CN (control, no medication, no MS provocation)
Number of subjects: 9
Study 20394809 — intervention group
Group type: COMPARATOR
Intervention: MS-CN, MS-P
Number of subjects: 9
Study 20394809 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-DMH
Number of subjects: 9
Study 20394809 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-Scop
Number of subjects: 9
Study 20394809 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 9
Study 19042267 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group (six meetings over 3 months)
Number of subjects: 29
Study 19042267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercises through biofeedback
Number of subjects: 29
Study 19042267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 16507196 — intervention group
Group type: EXPERIMENTAL
Intervention: prilocaine 1% 40 mL (G1)
Number of subjects: 96
Study 16507196 — intervention group
Group type: EXPERIMENTAL
Intervention: prilocaine 1% 30 mL and ropivacaine 0.75% 10 mL (G2)
Number of subjects: 96
Study 16507196 — intervention group
Group type: EXPERIMENTAL
Intervention: prilocaine 1% 20 mL and ropivacaine 0.75% 20 mL (G3)
Number of subjects: 96
Study 16507196 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.75% 40 mL (G4)
Number of subjects: 96